Solid Biosciences Inc expected to post a loss of 60 cents a share - Earnings Preview

Solid Biosciences

07/03/2025 13:17

Solid Biosciences Inc SLDB.OQ SLDB.O is expected to show no change in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Solid Biosciences Inc is for a loss of 60 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 0.9% in the last three months. ​

Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00​, above​ its last closing price of $5.50. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.81
-0.81
-1.00
Missed
-24
Sep. 30 2024
-0.66
-0.67
-0.79
Missed
-18.3
Jun. 30 2024
-0.66
-0.66
-0.61
Beat
8.1​
Mar. 31 2024
-0.65
-0.64
-0.64
Met
-0.1
​​Dec. 31 2023
-1.04
-0.99
-1.00
Missed
-1.2
Sep. 30 2023
-1.19
-1.19
-1.05
Beat
11.6​
Jun. 30 2023
-1.55
-1.53
-1.25
Beat
18.6
Mar. 31 2023
-2.21
-2.05
-1.50
Beat
26.9

This summary was machine generated March 7 at 13:17 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)